Agent   Study   Discontinuationproportion Proportion inthis study D4T Study 903 [14]   6% overall(wk 48) 13% overall(wk 144) 24.6% overall AZT Study 934 [15] 9% overall(wk 48) 18% overall   Package Insert [16 1.1% grade 3 or 4 anemia 8% due to anemia TDF Study 903 [14] 6% overall(wk 48) 0.7% overall   Study 934 [15] 8% overall(wk 144)   Study 907 [17] 4% overall NVP 2NN [18] 20.5% at least one grade 3 or 4adverse event7% (vs 5.9% for placebo) 6.6% overall Trial 1090 [19] 9% overall     Martínez et al. [20] ACTG 241 [21] 8% due to severe rash (vs. 2%placebo)     10% overall     INCAS [22]     EFV 2NN [18] 18% at least one grade 3 or 4adverse event 3.4% overall   DuPont006 [23] 1.7% rash, 2.1% CNS and 3% livertoxicity   LPV/r Study 720 [24] 13% overall 2% overall   Study 863 [25] 5.80%

Table 4: Comparison of discontinuation rates associated with antiretrovirals in various major trials/ package insert data.

Goto home»